SCM
FATE icon

Superstring Capital Management’s Fate Therapeutics FATE Stock Holding History

Superstring Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,379,556
Closed -$2.28M – 38
2024
Q4 		$2.28M Sell
1,379,556
-87,378
-6% -$220K 1.97% 15
2024
Q3 		$5.13M Buy
1,466,934
+969,574
+195% +$3.77M 4.49% 9
2024
Q2 		$1.63M Sell
497,360
-423,116
-46% -$1.85M 2.06% 13
2024
Q1 		$6.76M Buy
920,476
+72,653
+9% +$450K 4.47% 7
2023
Q4 		$3.17M Buy
+847,823
New +$2M 2.26% 16

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Superstring Capital Management's FATE Position: Q1 2025 in Review

Superstring Capital Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 1,379,556 shares — an estimated $2.28M sold.

Superstring Capital Management first reported a position in FATE in Q4 2023 and held it in 5 quarters. The position peaked at $6.76M in Q1 2024. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Superstring Capital Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Superstring Capital Management sold 1,379,556 Fate Therapeutics shares in Q1 2025, an estimated $2.28M.
  • Superstring Capital Management first reported a position in Fate Therapeutics in Q4 2023 and held it in 5 quarters.
  • Superstring Capital Management's Fate Therapeutics position peaked at $6.76M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.